Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of YL202 in selected advanced solid tumors
CTR20233371Phase 2Active
- Sponsor
- MediLink Therapeutics
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YL202 in non-small cell lung cancer (NSCLC), breast cancer, head and neck squamous cell carcinoma (HNSCC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by MediLink Therapeutics. Started Dec 2023; status: active.
02
Drugs
YL202
03
Conditions
non-small cell lung cancer (NSCLC)breast cancerhead and neck squamous cell carcinoma (HNSCC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20233371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233371.